CLAIMS

1. An insulinotropic peptide derivative, wherein N-terminal histidine residue of ~~the~~ a native insulinotropic peptide is substituted with ~~by a material selected from a group consisting of~~ 4-imidazoacetyl~~, N dimethyl histidyl, beta hydroxy imidazopropionyl and beta carboxyimidazopropionyl~~, and wherein the insulinotropic peptide is exendin-4, exendin-3 or derivatives thereof.

~~2. The insulinotropic peptide derivative as set forth in claim 1, wherein the insulinotropic peptide is selected from exendin-3, exendin-4 and the derivatives thereof.~~

~~3~~2. The insulinotropic peptide derivetive as set forth in claim ~~2~~1, wherein the insulinotropic peptide is exendin-4 or its derivative.

~~4~~3. The insulinotropic peptide derivative as set forth in claim 1~~ or 2~~, wherein the insulinotropic peptide derivative consists of an amino acid of the following Formula 1:

R1-X-R2 <Formula 1>

wherein R1 is ~~selected from the group consisting of~~4-imidazoacetyl~~, N dimethyl histidyl, beta hydroxy imidazopropionyl, and beta-carboxyimidazopropionyl~~;

R2 is selected from the group consisting of $-NH_2$ or -OH;

X is selected from the group consisting of Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly and Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser;

Y is selected from the group consisting of Lys, Ser, and Arg; and

Z is selected from the group consisting of Lys, Ser, and Arg.

~~5~~4. The insulinotropic peptide derivative as set forth in claim

~~4~~3, wherein R1 is 4-imidazoacetyl, Y is Lys or Ser, Z is Lys, and R2 is $-NH_2$.

~~6. The insulinotropic peptide derivative as set forth in claim 4, wherein R1 is N dimethyl histidyl, Y is Lys or Ser, Z is Lys, and R2 is $-NH_2$.~~

~~7. The insulinotropic peptide derivative as set forth in claim 4, wherein R1 is beta-hydroxy imidazopropionyl, Y is Lys or Ser, Z is Lys, and R2 is $-NH_2$.~~

~~8. The insulinotropic peptide derivative as set forth in claim 4, wherein R1 is beta-carboxy-imidazopropionyl, Y is Lys or Ser, Z is Lys, and R2 is $-NH_2$.~~

~~9~~5. A pharmaceutical composition for the treatment of diabetes, comprising the insulinotropic peptide derivative of claim 1.